Eagle Point Credit Company is experiencing net asset value pressure due to realized losses and rising interest rates, which is tightening its preferred equity coverage ratios. The Series C term preferred shares yield 7.3% to maturity but have limited asset coverage at 212%, raising concerns about risk if portfolio quality worsens. Mandatory redemption in 2031 and a 2% penalty for missed payments provide some protection, but given the elevated risks and narrow coverage buffer, a 'hold' rating is recommended for both common and preferred shares currently.
Eagle Point Credit's risk concerns provide context for financial sector trends on Pluang. For readers following Financials, here is Pluang's market snapshot as of Oct 23, 2026 21:12 WIB: among 142 priced US Financials-sector stocks, 13 rose and 128 fell. Notable movers include OWL at USD 9.44 with a 1-day change of -2.78% and a typical hold time of 8 days, SEZL at USD 135.46 with a 1-day change of -2.76% and Pluang order activity of 100% Sell, and UPST at USD 23.21 with a 1-day change of -2.68% and Pluang order activity of 100% Buy with a typical hold time of 39 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
